Advanced Search
ORIGINAL ARTICLES  
CMH 2013 December;19:399-408.
Published online 2013 December 29. doi:http://dx.doi.org/10.3350/cmh.2013.19.4.399
Copyright © 2013 The Korean Association for the Study of the Liver
  |  Abstract   |  PDF Links PDF Links   |   Download Citation
Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
Sang Hoon Ahn1,2,3*, Ji-Yong Chun4*, Soo-Kyung Shin4, Jun Yong Park1,2, Wangdon Yoo4, Sun Pyo Hong4, Soo-Ok Kim4, and Kwang-Hyub Han1,2,3
1Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul; 2Liver Cirrhosis Clinical Research Center, Seoul; 3Brain Korea 21 Project for Medical Science, Seoul; 4Research and Development Center, GeneMatrix Inc., Seongnam, Korea
Corresponding Author: Soo-Ok Kim ,Tel: +82-31-628-2088, Fax: +82-31-628-2001, Email: sookim@genematrix.net
ABSTRACT
Background/Aims: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study we evaluated the analytical and clinical performances of the HepB Typer-Entecavir kit (GeneMatrix, Korea) in detecting entecavir-resistance-associated mutations.
Methods: The HepB Typer-Entecavir kit was evaluated for its limit of detection, interference, cross-reactivity, and precision using HBV reference standards made by diluting high-titer viral stocks in HBV-negative human serum. The performance of the HepB Typer-Entecavir kit for detecting mutations related to entecavir resistance was compared with direct sequencing for 396 clinical samples from 108 patients.
Results: Using the reference standards, the detection limit of the HepB Typer-Entecavir kit was found to be as low as 500 copies/mL. No cross-reactivity was observed, and elevated levels of various interfering substances did not adversely affect its analytical performance. The precision test conducted by repetitive analysis of 2,400 replicates with reference standards at various concentrations showed 99.9% agreement (2398/2400). The overall concordance rate between the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical samples was 99.5%.
Conclusions: The HepB Typer-Entecavir kit showed high reliability and precision, and comparable sensitivity and specificity for detecting mutant virus populations in reference and clinical samples in comparison with direct sequencing. Therefore, this assay would be clinically useful in the diagnosis of entecavir-resistance-associated mutations in chronic hepatitis B.
Keywords: HBV; Drug; Resistance mutation; Entecavir; MALDI-TOF
Don't forget to sign up for journal e-mail alerts so you can keep up to date with all the articles as they are published.
e-submission
CMH
  
vol: Issue: Page:
  
Author's home
Reviewer's home
Editor's home
The Korean Association for the Study of the Liver
KoMCI
PubMed
PubMed Central
Sypapse
KoreaMed
CrossCheck
Crossref
Register for e-submission
Register here to access the e-submission system of CMH for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the CMH e-submission management system at http://submit.e-cmh.org, read the Instructions for Authors, and log into the CMH e-submission system. For assistance with manuscript submission, please contact: kasl@kams.or.kr.
Free archive
Anyone may access any past or current articles without logging in.
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero{MapoTrapalace , Dowha-dong}, Mapo-gu, Seoul, 121-784, Korea
TEL : +82-2-703-0051    FAX : +82-2-703-0071   E-mail : kasl@kams.or.kr
Copyright © By The Korean Association for the Study of the Liver. All right reserved.